Associated Papers
Whole-Genome Sequencing Reveals a Novel GATA2 Mutation in Lower-Grade Glioma: Bioinformatics Analysis of Functional and Therapeutic Implications.
Handoko et al.
Cancers, 2025
Custom Gene Panel Analysis Identifies Novel Polymorphisms Associated with Clopidogrel Response in Patients Undergoing Percutaneous Coronary Intervention with Stent.
Antúnez-Rodríguez A et al.
International Journal of Molecular Sciences, 2025
ABCC2 as a novel covariate influencing oxcarbazepine pharmacokinetics in pediatric epilepsy: Insights from population modeling.
Shen X et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1.
Aly SM et al.
Forensic Science International. Genetics, 2025
Genetic variants in patients with multiple arterial aneurysms.
Körfer D et al.
Langenbeck's Archives of Surgery, 2024
Genetic polymorphisms of drug-metabolizing enzymes in older and newer anti-seizure medications.
D'Onofrio G et al.
Expert Opinion on Drug Metabolism & Toxicology, 2024
In utero tumor development and identification of CTNNB1 mutation in a newborn case of ossifying renal tumor of infancy.
Kasai S et al.
Pediatric Blood & Cancer, 2024
Novel NARS2 variants in a patient with early-onset status epilepticus: case study and literature review.
Yang N et al.
Bmc Pediatrics, 2024
Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X et al.
European Journal of Pediatrics, 2023
The Effect of Genetic Variation on the Sensitivity to Opioid Analgesics in Patients With Postoperative Pain: An Updated Meta-analysis.
Li ZX et al.
Pain Physician, 2023
Polymorphisms Affecting the Response to Novel Antiepileptic Drugs.
Urzì Brancati V et al.
International Journal of Molecular Sciences, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma.
Seidel P et al.
Jci Insight, 2022
Genetic susceptibility of bladder cancer in the Lebanese population.
Kourie HR et al.
Bmc Medical Genomics, 2022
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C et al.
Pharmaceutics, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Wang ML et al.
Pharmacological Research, 2021
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.
Yip VLM et al.
British Journal of Clinical Pharmacology, 2021
Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa.
Pallerla SR et al.
International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases, 2021
Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation.
Zhao F et al.
Bmc Cancer, 2021
Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype.
Fonseca DJ et al.
Pharmacogenomics and Personalized Medicine, 2021
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.
Cacabelos R
International Journal of Molecular Sciences, 2020
A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions.
Calderon-Ospina CA et al.
Pharmacogenomics and Personalized Medicine, 2020
Whole-exome sequencing of 79 xenografts as a potential approach for the identification of genetic variants associated with sensitivity to cytotoxic anticancer drugs.
Udagawa C et al.
Plos One, 2020
Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy.
Xu ZY et al.
Frontiers in Pediatrics, 2020
Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.
Ayuso P et al.
The Journal of Antimicrobial Chemotherapy, 2019
Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Lin WW et al.
Therapeutic Drug Monitoring, 2019
Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A.
Oetting WS et al.
Transplantation, 2019
Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW et al.
European Journal of Clinical Pharmacology, 2019
Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects.
Zhu Q et al.
Frontiers in Pharmacology, 2019
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018
Genetics of acute rejection after kidney transplantation.
Dorr CR et al.
Transplant International : Official Journal of the European Society for Organ Transplantation, 2018
Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y et al.
European Journal of Clinical Pharmacology, 2017
Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.
Alkharfy KM et al.
Saudi Pharmaceutical Journal : Spj : the Official Publication of the Saudi Pharmaceutical Society, 2017
Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.
Fricke-Galindo I et al.
Pharmacogenomics, 2016
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N et al.
Clinical Pharmacokinetics, 2016
UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.
Chatzistefanidis D et al.
Pharmacogenomics, 2016
Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.
Liu L et al.
European Journal of Clinical Pharmacology, 2015
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh EM et al.
Pharmacogenetics and Genomics, 2015
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.
Claudio-Campos K et al.
Drug Metabolism and Personalized Therapy, 2015
SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy.
Ma CL et al.
Pharmacogenomics, 2015
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.
Swart M et al.
Frontiers in Genetics, 2015
Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption.
Bastami S et al.
Basic & Clinical Pharmacology & Toxicology, 2014
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Haas DW et al.
The Journal of Antimicrobial Chemotherapy, 2014